Article

Cytidine deaminase activity predicts clinical outcome of azacitidine in real-world MDS patients

2022-12-19

Abstract excerpt

Azacitidine (Vidaza®, Aza) is a mainstay for treating acute myeloid leukemia (AML) in patients unfit for induction chemotherapy and other high risk myelodysplastic syndromes (MDS). Only half of patients usually respond and almost all patients will relapse eventually. There are no predictive factors for response to Aza. Aza is detoxified in the liver by a single enzyme, cytidine deaminase (CDA). CDA is a ubiquitous...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8763f9a5-896e-508b-b04d-84c049e80d36
DOI: 10.21203/rs.3.rs-2370370/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cytidine deaminase activity predicts clinical outcome of azacitidine in real-world MDS patientsDOI 10.21203/rs.3.rs-2370370/v1Read

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.Semantic proximity Read

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.Semantic proximity Read

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomesSemantic proximity Read

Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.Semantic proximity Read

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity Read

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.Semantic proximity Read

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survivalSemantic proximity Read

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialSemantic proximity Read

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read

Efficacy and Safety of Azacitidine Plus Low-dose Dasatinib Maintenance Therapy for Patients with Intermediate and High-risk Acute Myeloid Leukemia: A Prospective, Randomized, Phase Ⅱ Clinical TrialSemantic proximity Read

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read